Anti-CD257 (BAFF) [5B7]
AB03782-10.0
ApplicationsFlow Cytometry, Neutralisation/Blocking
Product group Antibodies
ReactivityHuman, Monkey, Mouse
TargetTNFSF13B
Overview
- SupplierAbsolute Antibody
- Product NameAnti-CD257 (BAFF) [5B7]
- Delivery Days Customer9
- Application Supplier NoteThis antibody is capable of reacting with both soluble and membrane bound human, mouse and cynomolgus monkey BAFF/ BLyS protein. The binding ability of this antibody to membrane bound CHO-human BLys, HEK293-mouse BLyS and CHO-cynomolgus monkey BLyS protein was determined using flow cytometry. This antibody is capable of blocking the interaction between human BAFF and BR3. This antibody was also capable of neutralizing BLyS-mediated B-cell proliferation. The binding affinity characterization of this antibody was done using SPR. It was reported that the original IgG antibody binds human and mouse BLyS with a binding affinity of Kd= 4X10^(-10) M and Kd= 1.45X10^(-11) M respectively (US20170101466).
- ApplicationsFlow Cytometry, Neutralisation/Blocking
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone ID5B7
- Gene ID10673
- Target nameTNFSF13B
- Target descriptionTNF superfamily member 13b
- Target synonymsBAFF, BLYS, CD257, DTL, TALL-1, TALL1, THANK, TNFSF20, TNLG7A, ZTNF4, tumor necrosis factor ligand superfamily member 13B, ApoL related ligand TALL-1, B-cell-activating factor, B-lymphocyte stimulator, Delta4 BAFF, TNF and ApoL-related leukocyte expressed ligand 1, TNF homolog that activates apoptosis, delta BAFF, dendritic cell-derived TNF-like molecule, epididymis secretory sperm binding protein, tumor necrosis factor (ligand) superfamily, member 13b, tumor necrosis factor (ligand) superfamily, member 20, tumor necrosis factor ligand 7A, tumor necrosis factor superfamily member 13b, tumor necrosis factor-like protein ZTNF4
- HostHuman
- IsotypeIgG1
- Protein IDQ9Y275
- Protein NameTumor necrosis factor ligand superfamily member 13B
- ReactivityHuman, Monkey, Mouse
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC12352203




